Tirzepatide
Also known as GLP-2 dual agonist
Dual GIP/GLP-1 receptor agonist
A dual incretin analog studied for large reductions in body weight and improvements in glycemic markers.
How it works
Tirzepatide is studied as a dual agonist that binds both the GIP receptor and the GLP-1 receptor on pancreatic beta cells, the gut, and areas of the brain that regulate appetite. Activating both receptors at once appears to produce a stronger glucose and appetite signal than hitting either pathway alone, which researchers believe explains its larger effect sizes in trial data.
At the gut level, GLP-1 receptor activation slows gastric emptying, which extends the feeling of fullness after a meal and blunts the post-meal glucose spike. GIP receptor activity is thought to improve insulin sensitivity in fat and muscle tissue, complementing the glucose-lowering effect rather than duplicating it.
In the hypothalamus, combined receptor signaling reduces hunger-driving neuropeptide activity, which researchers link to the substantial reductions in caloric intake reported in trial populations. Because the compound is a long, modified peptide, it resists rapid enzymatic breakdown, allowing once-weekly dosing intervals in published protocols.
What research has shown
Phase 3 trial literature reports mean weight reductions of roughly 15 to 21% over 72 weeks at higher maintenance doses, with HbA1c reductions around 2%.
Reported ranges in the literature
Low end
2.5 mg weekly (titration / tolerance phase, typically 4 weeks)
Optimal
5 to 10 mg weekly after stepwise titration
High end
12.5 to 15 mg weekly, the ceiling used in published trials
Frequency reported in the literature: Once weekly. Note: Literature emphasizes 4-week titration steps to limit GI effects.
Frequently asked questions
What is tirzepatide studied for?
It is studied as a dual GIP and GLP-1 receptor agonist, most often in the context of body weight and glycemic control research. Trial literature reports substantial reductions in both body weight and HbA1c relative to placebo.
How does tirzepatide differ from semaglutide?
Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. Published trial comparisons generally report larger average weight reductions with tirzepatide, though individual response varies.
What does the research show on timeline?
Phase 3 literature reports progressive weight reduction over a 72-week period, with the steepest change typically occurring in the first 6 months before plateauing.
How is tirzepatide stored?
Lyophilized vials are stored refrigerated prior to reconstitution. Once reconstituted, stability data supports refrigerated storage for a limited number of weeks; researchers should reference current literature and their peptide calculator for precise conversion.
How long are research blocks typically?
Published trials commonly ran 72 weeks with stepwise titration during the first month, reflecting the time needed to assess durable weight and metabolic endpoints.
Related compounds
Further reading
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.